Indivior Pharmaceuticals (INDV) Non-Current Assets (2021 - 2026)

Indivior Pharmaceuticals' Non-Current Assets history runs 6 years deep, the most recent figure standing at $530.0 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 7.72% year-over-year to $530.0 million; the TTM figure through Mar 2026 stood at $2.1 billion (changed N/A YoY), while the FY2025 annual figure was $549.0 million, up 12.27% from the prior year.
• Non-Current Assets was $530.0 million for Q1 2026 at Indivior Pharmaceuticals, down from $549.0 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $691.0 million in Q4 2023 to a low of $489.0 million in Q4 2024.
• Historically, Non-Current Assets has averaged $532.0 million across 5 years, with a median of $505.5 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets surged 35.49% in 2023, then declined 29.23% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $510.0 million in 2022, then surged by 35.49% to $691.0 million in 2023, then dropped by 29.23% to $489.0 million in 2024, then climbed by 12.27% to $549.0 million in 2025, then retreated by 3.46% to $530.0 million in 2026.
• The last three Non-Current Assets figures came in at $530.0 million (Q1 2026), $549.0 million (Q4 2025), and $494.0 million (Q3 2025), per Business Quant data.